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G-protein-coupled receptors (GPCRs) are classified into A to F subfamilies in which only
families A, B, and C are present in mammals. Some of these GPCRs were found to form
higher ordered structures such as oligomers with the discovery of interacting receptors in
the form of homomers or heteromers. The importance of these oligomers on regulating
receptor functions has recently been an intense research focus. It has been proposed that
receptor oligomer formation has impact on its physiological importance on receptor traffick-
ing, signaling, ligand-related regulation, and also is related to certain diseases.The present
body of knowledge, however, comprises mainly intra-family oligomers formation and their
consequences. Inter-family oligomers are recognized but there is limited information. This
article aims to provide a current view regarding inter-family GPCR oligomerization in the
subfamilies A, B, and C found in mammals.
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INTRODUCTION
The vast structural and functional diversity of G-protein-coupled
receptors (GPCRs) makes it the largest membrane receptor fam-
ily. Members of the GPCR family include receptors responding to
hormones, neurotransmitters, lipids, photons, ions, nucleotides,
among others (1). It has been 20 years since GPCRs are classified
according to the A to F system by Kolakowski in 1994. Under
this system, only families A, B, and C are found in mammals
(2). For these three families of receptors, rhodopsin-like receptors
are classified as family A. Family B is further divided into three
subfamilies by Harmar into subfamily B1 (secretin-like recep-
tors), B2 (adhesion family), and B3 (Methuselah-like receptors)
(3). Family C comprises members having characteristic long N-
and C-termini and are responsible for sensing metabotropic glu-
tamate, Ca2+ ion, and γ-aminobutyric acid (GABA) (4, 5). The
concept of GPCRs oligomerization can be dated back to 1982
when Fraser and Venter discovered that β2-adrenergic receptors
(β2-AR) form dimers in the cell membrane. Their studies provided
the first piece of biophysical evidence of GPCR oligomerization
using immunoaffinity chromatography, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and radiation
inactivation techniques (6). Since then, receptor dimerization
events were demonstrated by co-immunoprecipitation (co-ip) and
resonance energy transfer approaches. Among the first studied
cases of GPCRs oligomerization, most effort had been focused
on family A GPCRs, while oligomerization in family B GPCRs
was largely neglected until Miller’s and Schelshorn’s groups pro-
vided information on such events in the past decade. The Miller’s
group described the homo-oligomerization of secretin recep-
tor (SCTR) (7, 8) and the heteromer formation of SCTR with
other family B GPCRs (8, 9), while Schelshorn’s group described
glucagon (GCG), glucagon-like peptide-1 (GLP1), glucagon-like
peptide-2 (GLP2), and gastric inhibitory polypeptide (GIP) recep-
tors oligomerization (10–12). Apart from providing biophysical
proof of GPCRs interactions, physiological consequences of such
interaction were also elucidated in the past 15 years when it was
gradually unveiled that oligomerization of receptors plays roles in
trafficking, ligand-promoted regulation, ligand binding, allostery,
as well as signal transduction (13). There also exist in vivo evidence
that dimerization of family B SCTR with family A angiotensin II
receptor type 1a (AT1aR) modulates the signaling properties of the
receptors (14). In view of the emerging emphasis on inter-family
GPCRs oligomerization and the functional importance of such
event, this article will review the basis of GPCRs oligomerization
emphasizing on family B GPCRs.
GPCR OLIGOMERIZATION
G-protein-coupled receptors were originally thought to function
as monomeric molecules, with a 1:1 stoichiometry for one receptor
protein to interact with one heterotrimeric G protein (13). How-
ever, with the advancement in receptor biology research, GPCR
homo- and/or hetero-oligomerization is now generally accepted
as a common phenomenon. Although the exact stoichiometry of
such interaction remains mostly undetermined under the cur-
rent limitation of technical difficulties, oligomers of GPCRs have
proved to involve in vital roles in terms of functioning of the
receptors.
For family A GPCRs, evidences have suggested dimerization as
a prerequisite for correct trafficking as well as signaling of cer-
tain receptors. Examples are somatostatin receptor and adrenergic
receptors (15, 16). Ligand may also regulate the oligomeric state
of receptors on the cell surface, either positively for the luteinizing
hormone receptor (17) or negatively for the thyrotropin receptor
(18). Ligand binding cooperativity was observed to be altered in
M2 muscarinic receptor dimers (19).
For family C receptors, receptor oligomerization is essential
to the proper functioning of the protein. A classic example is
the GABAB receptor (GABABR), which is the heterodimer of the
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protomers GABAB1R and GABAB2R. The ligand binding site is
located on GABAB1R but transportation to the cell membrane as
well as G-protein coupling for proper functioning of the receptor
can only be achieved when GABAB2R is present and heterodimer-
izes with GABAB1R (20, 21). The significance of family B receptors
oligomerization will be discussed later in this article.
METHODS TO STUDY OLIGOMERIZATION OF GPCRs
Traditionally, co-ip was used to study receptor oligomers. Obser-
vations of oligomer formation in GPCRs primarily rest upon on
this technique since the first report by Hebert et al. (22) describing
β2-AR receptor dimers (22). However, due to the technical diffi-
culties, methods utilizing the resonance energy transfer between
receptors tagged with luminescent or fluorescent proteins have
become more popular. In one of the methods, known as biolumi-
nescent resonance energy transfer (BRET), one of the receptor is
tagged usually at the C-terminus with the enzyme Renilla luciferase
(Rlu), which acts as the donor molecule, while the acceptor recep-
tor is tagged with a yellow or green fluorescent protein (YFP/GFP).
The two receptor constructs are co-expressed in vitro, usually in
the form of a saturation experiment when a constant amount of
the donor molecule is co-transfected with an increasing amount
of acceptor receptors. Upon Rlu activation by its specific sub-
strate, light energy from the reaction can be transferred and excite
the acceptor fluorescent protein when the two receptors are in
a proximity of <10 nm apart. This fluorescence of the accep-
tor emission can then be quantified as an indicator of receptor
interactions known as the BRET signal. For specific interaction,
the BRET signal will increase with increasing concentration of
acceptor receptor, indicated by a saturation curve. Negative con-
trol is provided as a linear straight line when the BRET signal is
produced by the random collision of tagged receptors. The advan-
tages of using BRET methods over co-ip is that BRET improves
resolution and more importantly, enable faster screening of dimer-
ization partners (23, 24). Another similar technique replaces the
Rlu with a cyan fluorescent protein (CFP), and requires the acti-
vation of CFP by laser for resonance energy transfer. This method
is known as FRET and eliminates the use of substrate and is pri-
marily useful in applications to study receptor trafficking under
the microscope. However, it suffers the disadvantage of having
to employ linear unmixing algorithms in the microscope soft-
ware due to the possible crosstalk of fluorescent signals from the
two fluorescent protein tags (25). An improvement to this situa-
tion relies on the use of long-lived rare-earth lanthanides energy
donors, such as europium. This time-resolved FRET technique
lowers the background signal and hence a higher signal:noise
ratio can be obtained over normal FRET procedures (26). Other
fluorescent based technologies include bimolecular fluorescence
complementation and bimolecular luminescence complementa-
tion. These experiments use receptors tagged with a part of the
fluorescent/luminescent protein that, upon receptor oligomeriza-
tion, can reassemble into functional protein again (27). Although
there exist different approaches to probe for receptor oligomers,
most experimental evidence of the physiological consequences of
these GPCRs interactions were only found in the in vitro model.
In vivo evidence was poorly lacking until the demonstration of the
phenotypes of luteinizing hormone receptor transgenic mice in
2010 (17), and water homeostasis effect of angiotensin II (ANGII)
and SCTR homomers and heteromers in 2014 (14).
OLIGOMERIZATION OF FAMILY B GPCRs AND ITS
FUNCTIONAL SIGNIFICANCE
Among the family B GPCRs, the SCTR is the first member of
the family cloned from rat (28) and thus is the most comprehen-
sively studied. Using primarily BRET technique, the Miller group
provided evidences on SCTR homodimerization (8, 29, 30), as
well as heterodimer formation with glucagon-like peptide-1 recep-
tor (GLP1R), glucagon-like peptide-2 receptor (GLP2R), vasoac-
tive intestinal peptide receptors 1 and 2 (VPAC1R, VPAC2R),
growth hormone-releasing hormone receptor (GHRHR),parathy-
roid hormone 1 receptor (PTHR1), parathyroid hormone 2 recep-
tor (PTHR2), and calcitonin receptor-like receptor (CRLR) (8,
9). The specific sites of interaction of SCTR homodimer were
the transmembrane 4 of the receptor in which Gly243 and Ile247
residues play a key role (29).
For other members of the family, intra-family homo-
mers includes GLP1R, GLP2R, gastric inhibitory polypeptide
receptor (GIPR), glucagon receptor (GCGR) (10–12), PTHR1
(31), VPAC1R, VPAC2R (8), GHRHR (32), calcitonin receptor
(CALCR) (33), CRLR (34), corticotrophin-releasing hormone
receptor 1 (CRHR1) (35, 36), and pituitary adenylate cyclase-
activating polypeptide type I receptor (PAC1) (37), while intra-
family heteromers include VPAC1R/VPAC2R (8), GLP1R/GIPR,
GLP1R/GCGR,GLP1R/GLP2R,GCGR/GIPR,GCGR/GLP2R,and
GIPR/GLP2R (10–12).
For the family B receptors, physiological relevance of dimeriza-
tion was mainly demonstrated by in vitro experiments. First being
the dominant negative effect of a mis-spliced SCTR on wildtype
SCTR, leading to gastrinoma development (7). The importance
of dimerization for receptor trafficking is observed both in SCTR
and VPAC1R in which non-dimerizing receptor constructs failed
to reach the cell surface (8, 29, 30).
Although no effect was observed for SCTR homodimers
(8), ligand binding can negatively affect dimer formation of
VPAC1R/VPAC2R/PTHR1 homo/heterodimers (8, 9, 31). Inter-
estingly, GLP1 can positively affect dimer formation for GLP1R
and GIPR dimer, while GIP has inhibitory effect on the hetero-
complex formation (12, 38). In addition to ligand affecting dimer
formation, formation of dimer has an effect on ligand binding
as well. Using transmembrane domain 4 (TM4) peptide to dis-
rupt GLP1R homodimer formation, binding of the ligand GLP1
(7–36)-NH2 can be nullified (39). Truncated GHRHR can also
lead to conformational change in the dimer complex, which is
responsible for the inhibition of GHRH ligand binding (32).
Most family B GPCRs elicit their functions through the cAMP
and/or phospholipase C (PLC) signaling cascade. The effect of
oligomerization on the cellular mobilization of cAMP and cal-
cium was also one of the research areas in GPCR oligomerization
studies. In 2007, it was found that by disrupting SCTR homod-
imer formation using TM4 peptide, cAMP production is reduced
(29). GLP1R and GIPR dimer is also known to decrease the max-
imal responses of GLP1R in terms of β-arrestin recruitment and
calcium mobilization (38, 39). Taken together, oligomerization of
GPCRs plays vitally important roles on multiple aspects of cell
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physiology. Table 1 outlines the intra-family oligomerization of
family B GPCRs, the techniques involved and the physiological
significance included.
INTER-FAMILY GPCRs OLIGOMERIZATION
Since the maturation of the concept of GPCR oligomerization, its
functional implications are gradually understood and appreciated.
Experimental evidences on oligomer formation as well as physio-
logical importance has been accumulating first in families A and C,
then in family B members in the past years. However, most studies
so far has been focusing on intra-family receptor oligomerization,
inter-family events are poorly understood. The fact that there exist
little sequence homology between families A, B, and C receptors,
despite having shared common general morphology, may explain
this scarcity of information (5, 40). Up till now, documented inter-
family events include family B GIPR with family A members β2-AR
and opsin. In their experiment, they use the BRET method in a
heterologous expression system to discover that cAMP production
is increased upon ligand stimulation compared to monomers (41).
Family B CRHR1 with family A vasopressin receptor 1b (V1bR)
was studied again using the BRET technique but instead of tagging
the receptors at the C-termini, they are tagged at the N-termini
(36). Family B GCGR with family A cholecystokinin A receptor
was also reported (CCKAR) (10). Among these, family B SCTR
with family A AT1aR shows the most convincing evidence. Based
on the observation that both drinking behavior and vasopressin
expression and release are impaired in secretin (SCT) or SCTR
knockout mice upon intracerebroventricular (i.c.v.) injection of
ANGII (42), it was deduced that a SCT/SCTR axis is essential to
the proper functioning of ANGII in the central nervous system.
With the coexpression of AT1aR and SCTR in the paraventricular
nucleus, receptor heterocomplex formation was hypothesized to
Table 1 | Oligomerization of intra-family family B GPCRs.
Oligomer Technique Physiological significance Reference
HOMOMERS
SCTR/SCTR BRET/FRET Relation with gastrinoma;
promotes cAMP response
Ding et al. (7), Harikumar et al. (8, 29)
GLP1R/GLP1R BRET Promotes ligand binding Orgaard (10), Roed (11), Schelshorn et al. (12),
Harikumar et al. (39)
GLP2R/GLP2R BRET N/A Schelshorn et al. (12)
GIPR/GIPR BRET N/A Schelshorn et al. (12)
GCGR/GCGR BRET N/A Orgaard (10), Roed (11), Schelshorn et al. (12)
PTHR1/PTHR1 BRET/FRET Ligand reduces oligomerization Pioszak et al. (31)
VPAC1R/VPAC1R Co-ip/BRET/FRET Ligand reduces oligomerization Harikumar et al. (8)
VPAC2R/VPAC2R BRET/FRET Ligand reduces oligomerization Harikumar et al. (8)
GHRHR/GHRHR Co-ip Promotes ligand binding McElvaine and Mayo (32)
CALCR/CALCR Co-ip/BRET/FRET Alters receptor trafficking Seck et al. (33)
CRLR/CRLR Co-ip/BRET/FRET N/A Heroux et al. (34)
CRHR1/CRHR1 FRET/BRET N/A Kraetke et al. (35), Young et al. (36)
PAC1/PAC1 Time-resolved FRET N/A Maurel et al. (37)
HETEROMERS
SCTR/GLP1R BRET N/A Harikumar et al. (9)
SCTR/GLP2R BRET N/A Harikumar et al. (9)
SCTR/VPAC1R FRET/BRET Receptor trafficking Harikumar et al. (8, 9, 29)
SCTR/VPAC2R FRET/BRET Receptor trafficking Harikumar et al. (8, 9, 29)
SCTR/GHRHR BRET N/A Harikumar et al. (9)
SCTR/PTHR1 BRET Ligands reduce oligomerization Harikumar et al. (9)
SCTR/PTHR2 BRET Ligands reduce oligomerization Harikumar et al. (9)
SCTR/CRLR BRET N/A Harikumar et al. (9)
GCGR/GLP1R BRET N/A Orgaard (10), Roed (11), Schelshorn et al. (12, 38)
GCGR/GLP2R BRET None Schelshorn et al. (12, 38)
GCGR/GIPR BRET None Schelshorn et al. (12, 38)
GIPR/GLP1R BRET GLP-1 induces oligomerization and flattened
Ca2+ response; GIP reduces oligomerization
but does not alter Ca2+ response
Harikumar et al. (39), Schelshorn et al. (12, 38)
GIPR/GLP2R BRET None Schelshorn et al. (12, 38)
GLP1R/GLP2R BRET N/A Orgaard (10), Roed (11), Schelshorn et al. (12, 38)
VPAC1R/VPAC2R Co-ip/BRET Ligand reduces oligomerization Harikumar et al. (8)
Technique involved and physiological significance are described; N/A, information not available.
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be the reason behind this observation. By using BRET techniques,
it was found that SCTR interacts with AT1aR specifically, but not
angiotensin II receptor type 2 (AT2R). When the receptors were
expressed together in vitro and stimulated with SCT alone, cAMP
response was blunted compared to cells bearing only SCTR or
SCTR with the non-dimerizing AT2R. However, cAMP produc-
tion could be restored when ANGII was also present or when
SCTR was co-expressed with a constitutively active mutant AT1aR,
but not with the ANGII binding-deficient mutant AT1aR-K199A.
Together with the fact that AT1aR cannot stimulate the cAMP
signaling pathway, it was concluded that an active conformation
of the AT1aR was responsible for regulating SCTR in mediating
cAMP responses. In line with previous finding (29), the role of TM
peptides on heterocomplex formation was also elucidated. It was
found that peptides derived from SCTR’s TM 2 and 4 (STM-II/IV),
and AT1aR’s TM 1 and 4 (ATM-1/4), could inhibit heteromer for-
mation, while only STM-IV or/ATM-4 peptides could suppress
the homomers of SCTR or AT1aR, with alanine mutants of these
peptides reversing the situation. ATM-1 was chosen to investigate
heteromer-specific actions as this peptide is neither capable of dis-
rupting SCTR nor AT1aR homomer formation. By using these TM
peptides as a tool, specifically ATM-1 and its mutant counterpart,
it was demonstrated that full activity of SCT-stimulated SCTR
requires the activation of AT1aR as a prerequisite. To further inves-
tigate the physiological relevance of SCTR/AT1aR heteromer in
relation to water homeostasis, i.c.v. injections of the TM peptides
and their mutants were administered to mice under hyperosmo-
lality stress. All the four aforementioned TM peptides can suppress
drinking behavior of these mice under hyperosmolality to differ-
ent degrees. Of which, STM-IV, ATM-1, and ATM-4 can inhibit
drinking behavior to a level similar to that of SCTR knockout
mice or mice injected with the protein kinase A inhibitor H89, for
the case of STM-II the effect was not as prominent. These results
were reversed when the alanine mutants TM peptides were used
instead. The experiments demonstrate that receptor heterocom-
plex of SCTR and AT1aR plays a role in regulating water drinking
behavior in vivo. Furthermore, i.c.v. injection of a combination of
low doses of both SCT and ANGII produces an effect on drinking
behavior comparable to injection of high doses of these hormones
alone, which is significantly greater than that when the hormones
were given singly at low doses. This synergistic effect of the hor-
mones in the central nervous system hints that the physiological
effect of SCTR can be prominently enhanced with ANGII. This
important study strongly suggests the significance of inter-family
heterodimer formation on physiology (14). Table 2 summaries the
heteromer formation of inter-family GPCRs.
CONCLUSION AND FUTURE PERSPECTIVE
Since there is a growing body of evidences on the functional
importance of GPCR oligomerization but information on poten-
tial oligomerizing partners within families A, B, and C is lacking;
the area of GPCRs oligomerization within these families is being
explored in our laboratory recently. Initial approach includes set-
ting up a GPCR–YFP library with GPCRs tagged with YFP. Using
this scheme, any GPCR having tagged with Rlu can be screened
against this library for oligomer partners. Not only can this study
compensate our current paucity of information on inter-family
Table 2 | Oligomerization of inter-family family B GPCRs.
Heteromers Technique Physiological
significance
Reference
GIPR/β2-AR BRET Potentiates cAMP
responses
Vrecl et al. (41)
GIPR/opsin BRET Potentiates cAMP
responses
Vrecl et al. (41)
CRHR1/V1bR BRET N/A Young et al. (36)
GCGR/CCKAR BRET N/A Orgaard (10)
SCTR/AT1aR BRET/FRET Reduces secretin’s cAMP
response; alters drinking
behavior
Lee et al. (14)
Technique involved and physiological significance are described; N/A, information
not available.
GPCR oligomers but also the cellular co-localization of these
partners and their physiological relevance can be elucidated. If
the receptors are found to be co-localized and serving similar
functions, further biochemical analysis can be made to assay for
the functional significance of the receptor interaction. As such,
a number of novel mechanisms in controlling cellular activities
may be discovered. Such discoveries could in turn facilitate the
development of biochemical tools for scientific research or in vitro
diagnostics. As around 30–40% of the pharmaceutical drugs at
present are targeting GPCRs, this basic research on the role of
GPCR oligomerization may pave the path for developing pharma-
ceutical precursors, which may eventually become the answers to
a variety of diseases.
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